Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.54 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Citrulline SCHEMBL20588 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL215403 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL288641 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20587 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL9070200 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL437142 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL4542892 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL15909604 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL22426116 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20742804 | 0.98 | OTC (0.57) | OTCDDAH1GSRNOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024194498-A2 | CROSS REACTIVE MICROBIAL PEPTIDE CANCER VACCINE AND T CELL RECEPTORS REACTIVE THERETO | Universität Zürich (CH) | 2024-09-26 | — | — | WO | disclosed |
| US-12043845-B2 | Methods of cell culture | POLPHARMA BIOLOGICS S.A. (PL) | 2024-07-23 | — | — | US | disclosed |
| US-12043845-B2 | Methods of cell culture | POLPHARMA BIOLOGICS S.A. (PL) | 2024-07-23 | — | — | US | disclosed |
| WO-2024149616-A1 | FERMENTATIVE PRODUCTION GUANIDINOACETIC ACID (GAA) FROM SERINE USING A MICROORGANISM HAVING AN ENHANCED L-SERINE HYDROXYMETHYLTRANSFERASE ACTIVITY | EVONIK OPERATIONS GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024149617-A1 | FERMENTATIVE PRODUCTION GUANIDINOACETIC ACID (GAA) FROM SERINE BY ATTENUATING L SERINE AMMONIA LYASE ACTIVITY IN MICROORGANISMS | EVONIK OPERATIONS GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151843-A1 | TARGETED UNIVERSAL DELIVERY SYSTEM OF DON AND OTHER DRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12036206-B2 | Compositions and methods for pain relief | CROSS III WILLIAM H (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036206-B2 | Compositions and methods for pain relief | CROSS III WILLIAM H (US) | 2024-07-16 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080227152-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008073918-A1 | NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007038658-A2 | ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MEDAREX, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NSUN2, NSUN3, POLRMT | OTC 281/4885DDAH1 830/4885GSR 3021/4885 |
| US-12036206-B2 | Compositions and methods for pain relief | CBS, CTH, CPT1B | OTC 168/4885DDAH1 1438/4885GSR 387/4885 |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | SLC6A3, AADAT, SLC6A2 | OTC 337/4885DDAH1 67/4885GSR 2538/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | OTC 4846/4885DDAH1 1170/4885GSR 4580/4885 |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | OTC 4038/4885DDAH1 2254/4885GSR 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.